Volume 90 Issue 37 | Latest News
Web Date: September 6, 2012

Germany’s Merck Reshapes Business

Specialties: Cutbacks will impact jobs in chemicals and drugs
Department: Business
Keywords: pharmaceuticals, specialty chemicals, employment, restructuring
[+]Enlarge
A new materials research center is part of Merck’s refocused operations in Darmstadt, Germany.
Credit: Merck KGaA
ACS: Candidates' Election Statements And Backgrounds
 
A new materials research center is part of Merck’s refocused operations in Darmstadt, Germany.
Credit: Merck KGaA

Merck KGaA, the German specialty chemical and pharmaceutical company, is now cutting jobs at home. As it continues its six-month-old “Fit for 2018” program, the Darmstadt-based firm is trying to address competitive shifts while freeing up resources for investment.

By the end of 2015, Merck plans to eliminate about 1,100 of 10,900 positions in Germany. Cuts will come primarily from voluntary resignations and early retirements. The company says it will avoid layoffs until the end of 2017, except those from possible site closures still being reviewed.

Merck is moving ahead only after months of negotiating with employee unions. “It is particularly important that there will be no forced redundancies in Darmstadt and Gernsheim through the end of 2017, and we were largely able to avoid outsourcing of jobs,” union representative Heiner Wilhelm says about the agreement.

However, Merck has decided to end industrial salts production in Lehrte, Germany, and filling operations in Hohenbrunn. These closures will affect about 140 employees.

At the same time, Merck wants to make Darmstadt a “state-of-the-art production and research center” for both pharmaceuticals and chemicals. To do so, it intends to invest at least $315 million there and at other German sites over the next two years.

The plans for Germany follow cuts to the Merck Serono drug unit in Switzerland that began in June. The unit will move its headquarters to Darmstadt after closing a site in Geneva by mid-2013 and one in Coinsins in 2014. About 500 jobs will be eliminated and 750 employees will be transferred. Another 1,000 people will remain at three other Swiss sites.

To end labor disputes in Switzerland, Merck hammered out a severance and redeployment package with the local union. The company also created a $38 million fund to support ventures started by departing employees. So far, Merck has helped set up Prexton Therapeutics around former neurodegenerative disease assets and a biomarker analysis firm called Quartz Bio.

Despite having one of Europe’s strongest economies, Germany has recently seen its growth slow. “Labor market indicators have been developing more and more weakly,” Federal Employment Agency Chairman Frank-J. Weise reported on Aug 30. VCI, the country’s chemical industry association, predicted last week that German chemical production will drop 3% this year compared to 2011. VCI earlier anticipated that output would remain level.

Merck’s efficiency plan was put in place after management changes in late 2011. In June, the company noted that cost efficiencies and lower spending had already contributed to more than 20% earnings growth, before restructuring charges. Citibank stock analyst Mark Dainty called it “clear evidence that new management is managing the business for value and growth.”

Last week, Merck said further cost savings will result from a restructuring of its employee compensation system. As of June, Merck had 40,085 employees. It has not yet announced reorganization moves at its other worldwide sites, although they are anticipated.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment